What does a fractional CRO do for a medical device business in 2027?

The job this role is actually hired to do

Medical device companies rarely hire a fractional CRO because they lack sellers. They hire one because revenue has become unpredictable in a way nobody inside the building can diagnose. Reps are busy, demos are happening, surgeons say encouraging things in the hallway, and the forecast still misses by a wide margin every quarter. The founder or CEO cannot tell whether the problem is the product, the pricing, the territory design, or the fact that nine of the top fifteen deals are stalled inside a value analysis committee that no one on the team has ever met.

The fractional CRO is hired to make revenue legible. That is the job in one sentence. Everything else — methodology rollouts, CRM cleanup, comp plan redesign, channel decisions — is downstream of turning a vague pipeline into a set of deals whose stage, owner, blocker, and realistic close date are all knowable facts rather than opinions.

In a medical device business this diagnosis has a shape that generic B2B leadership does not anticipate. The first thing a competent fractional CRO does is separate the sales problem from the adoption problem. A hospital purchase is not one decision; it is usually three. There is the clinical decision — does a surgeon or clinician want to use this device instead of what they use now. There is the economic decision — will the value analysis committee, supply chain, or contracting group approve adding a new vendor and a new SKU to a system that is actively trying to reduce vendor count. And there is the operational decision — can the facility actually absorb the device, meaning trays get reprocessed, staff get trained, the rep gets credentialed, and the item gets loaded into the materials management system. Deals die at any of the three, and they die for different reasons, and they require different interventions. A pipeline that does not distinguish among them produces a forecast that is essentially noise.

So the early work is unglamorous. Expect the first four to six weeks to be spent on deal inspection rather than strategy. A typical opening pass looks like this: pull every open opportunity above a materiality threshold, sit with the owning rep for twenty to thirty minutes each, and ask the same short list of questions. Who wrote the request or raised their hand first, and are they still engaged. Has anyone from your side spoken to whoever runs value analysis at this account. Is there a comparable device already under contract, and when does that contract come up. What specifically has to happen between today and a purchase order, listed in order, with names. What is the last thing that happened that the customer initiated rather than you.

That last question is the single highest-yield diagnostic in device sales. Deals that only move when the rep pushes are almost always dead and have not been reported as dead. In most first passes through a device pipeline the honest reclassification removes somewhere between a quarter and a half of the reported dollar value. This is the moment where the engagement either builds trust or breaks it. A good fractional CRO frames the cut as a clarity win rather than an indictment, and immediately pairs it with a specific plan for rebuilding coverage, because a CEO who sees the pipeline halved with no replacement plan will reasonably panic.

The second piece of the job is deciding what the revenue motion should be, which in device businesses is mostly a channel and coverage question. Direct sales reps carrying a bag are expensive, typically the most expensive customer acquisition channel a device company will run, and they are the right answer for capital equipment and high-complexity implants where case coverage and clinical support are inseparable from the sale. Independent distributors or manufacturer's reps are cheaper on a fixed-cost basis and give instant relationships in a territory, but they carry lines from multiple manufacturers, so mindshare is bought rather than assumed, and a distributor with a large incumbent line will not fight hard for a challenger product. Hybrid models — direct in a handful of proving-ground territories, distributor everywhere else — are common and are usually the right answer for a company under roughly thirty million in revenue that cannot fund national direct coverage.

The fractional CRO's contribution here is not the idea that these options exist; every founder knows that. It is the discipline of picking one deliberately, writing down what result would prove it right within two quarters, and then actually reading the result. Device companies routinely run both models simultaneously without ever comparing them, which means they pay for two go-to-market systems and learn from neither.

The third piece is the people decision, and it is the one clients most often want the fractional CRO to make for them because it is uncomfortable. On a small device sales team of six to fifteen reps, the distribution of production is usually extreme — a couple of reps carrying most of the number, a middle group that is roughly break-even after fully loaded cost, and a tail that is losing money. The fractional CRO's role is to build the evidence base for those calls, define what good looks like in territory terms rather than personality terms, and give the CEO a defensible framework. What they should not do is fire people in month one. Territory quality varies enormously in device sales; a rep with three academic medical centers and no existing contract vehicle is playing a different game than one inheriting a book of long-standing community hospital accounts.

Finally, the fractional CRO is hired to be the person who talks to the board about revenue in a language the board recognizes. For venture- or PE-backed device companies, this matters more than it sounds. A CEO who is a clinician or an engineer by background can be brilliant on product and still lose the room when the conversation turns to coverage ratios, cohort retention on reorders, and why the sales cycle extended by two months. Having a revenue executive who can present that material calmly, with numbers that tie out, changes the temperature of board meetings and buys the company time.

How it fits the RevOps stack

The fractional CRO does not usually run the tools personally. They define what the revenue system has to answer, and then either direct an existing ops person or bring a RevOps contractor to build it. In a device business the stack question is narrower than in SaaS because the underlying data is different: revenue is often tied to physical inventory, consignment sets, case usage, and contract pricing tiers, not to seats and subscriptions.

A practical minimum viable stack for a device company between five and fifty million in revenue looks like this. A CRM as the system of record, almost always Salesforce or HubSpot, configured around the actual device milestone sequence rather than the default template. A source of truth for accounts that reflects health system hierarchy — meaning the individual hospital rolls up to its parent system, because that is where contracting decisions increasingly live. Some form of activity capture so that engagement is recorded without depending on rep diligence. A reporting layer, which for smaller companies is often just well-built CRM dashboards rather than a separate revenue intelligence platform. And a connection between the CRM and whatever ERP or order system holds actual shipments, because in device businesses the gap between "closed won" and "revenue recognized" can be months and is where a lot of forecasting error lives.

Stage design is where the fractional CRO adds the most technical value, and it is worth being concrete. The default CRM stages — qualification, proposal, negotiation, closed — describe a transaction that does not resemble a hospital purchase. A stage set that actually works for a device sale tends to track institutional gates: clinical interest established with a named champion; evaluation or trial agreed and scheduled; evaluation completed with documented outcome; value analysis submission prepared and submitted; value analysis decision received; contracting and pricing agreed; purchase order issued; first case or installation completed. Each stage should have an exit criterion that is a verifiable artifact — a signed trial agreement, a submitted VAC packet, a returned decision, a PO number — rather than a feeling about momentum.

The reason this matters is forecasting. When stages map to institutional artifacts, historical conversion rates between stages become meaningful, and a forecast becomes arithmetic rather than intuition. When stages map to rep sentiment, every forecast is a mood reading, and no amount of AI layered on top will fix it. This is the most common thing a fractional CRO finds and repairs.

On qualification method, MEDDPICC is the common choice in device sales and it fits, provided the fields are translated into hospital terms rather than applied as generic sales vocabulary. Metrics means the specific clinical or economic outcome the account will measure — OR minutes, length of stay, revision rate, cost per procedure. Economic buyer in a health system is frequently not the clinician and frequently not one person; it is the value analysis committee or a supply chain executive with delegated authority. Decision criteria almost always include a formal review process with a submission template. Paper process includes credentialing, GPO or IDN contract eligibility, and legal review of the vendor agreement — steps that are invisible in generic B2B and that routinely add sixty to ninety days. Champion means someone willing to present internally on your behalf, which is a much higher bar than someone who likes the product. Competition includes the incumbent contract and its renewal date, not just the rival product.

AI's real contribution in 2027 device revenue work is narrower than the marketing suggests, and a good fractional CRO will say so out loud. Where it genuinely helps: automatic capture and summarization of customer conversations so that deal notes exist without rep effort; flagging opportunities with no customer-initiated activity in a defined window; drafting first-pass evidence summaries tailored to different committee audiences; and reducing the administrative load that keeps device reps out of the OR and in their cars doing CRM hygiene. Where it does not help: predicting the outcome of a value analysis committee meeting at a single hospital from thin historical data. Most device companies do not have enough closed opportunities for a model to learn a reliable pattern, and a confident-looking probability score built on eighty deals is worse than no score, because people believe it.

The pragmatic position is to use AI for data capture and summarization, keep the forecast anchored to stage conversion math and rep commit calls, and revisit predictive scoring only when the historical dataset is large enough to validate against.

Pricing, engagement models, and typical ranges

Fractional CRO engagements price in a few recognizable structures, and understanding them protects a device business from buying the wrong shape of help.

The most common structure is a monthly retainer tied to a defined number of days. Two days a week is the typical midpoint. One day a week is realistically advisory — enough for pipeline review and coaching, not enough to rebuild a go-to-market motion. Three days a week starts to approximate an embedded executive and is appropriate during a turnaround, a launch, or a period when the company has no sales leadership at all. Retainers are usually quoted monthly, with an initial term of three to six months and a rolling renewal after that.

The second structure is a diagnostic-then-engage model. A fixed-fee assessment lasting two to six weeks produces a written revenue diagnosis — pipeline reality, coverage math, stage integrity, team assessment, channel recommendation — and the client then decides whether to continue into an ongoing retainer. This is a good way to buy for a company that is unsure, because the assessment has standalone value even if the relationship ends there. It also protects the fractional CRO from being blamed for a number they had no time to influence.

A third structure adds variable compensation. This can be a bonus tied to specific milestones — a hire made, a methodology adopted with measurable stage-conversion improvement, a distributor agreement signed — or tied to revenue or bookings against plan. Milestone bonuses tend to work better than revenue-share in device businesses, for a simple reason: the sales cycle is long enough that revenue booked during a six-month engagement was largely created before the fractional CRO arrived, and revenue created during the engagement will close after they leave. Paying on revenue in a fourteen-month cycle pays the wrong person for the wrong quarter.

Equity sometimes appears, usually as a small advisory grant with standard vesting, most often at seed or Series A companies conserving cash. Treat equity as a supplement, not as a discount lever. An executive who materially reduces their cash rate for equity is taking a founder's risk on someone else's cap table, and the ones worth hiring generally will not.

On magnitude, the honest framing to give a CEO is a comparison rather than a number. A full-time CRO at a device company carries base salary, variable compensation, equity, benefits, payroll taxes, and recruiting cost — and the recruiting cost alone for a senior revenue executive is typically a meaningful percentage of first-year cash compensation. A fractional engagement at two days a week is a fraction of that fully loaded cost, with no severance exposure and a notice period usually measured in weeks. That structural difference — not the day rate — is the actual economic argument.

Rates themselves vary widely by market, by the executive's track record, and by whether the engagement is advisory or operational, so any specific figure quoted as universal should be treated skeptically. What a buyer should do instead is ask for the day-rate math explicitly: total monthly fee divided by committed days, so that two proposals can be compared on the same basis. Proposals that resist that arithmetic are usually hiding either a low day count or a high effective rate.

There are also engagement costs that are easy to miss. Travel matters more in device businesses than in software, because a revenue leader who never visits a hospital, never watches a case, and never sits with a distributor principal will not earn credibility with the sales team. Budget for it and agree the policy up front. Tooling changes may require a CRM administrator or implementation partner, which is a separate line item. And if the engagement includes hiring, recruiting fees for device sales talent are their own cost and should not be assumed to sit inside the retainer.

The final pricing consideration is the exit. A well-structured engagement defines what handoff looks like from the beginning: documented playbooks, a stage-defined CRM, a hired or promoted internal leader, and a transition period. Engagements without a defined endpoint have a tendency to become permanent at a price that eventually exceeds what a full-time hire would have cost, which defeats the purpose.

How to evaluate and shortlist candidates

The market for fractional executives has grown quickly, and growth has brought a wide quality spread. Some candidates are genuinely former operators who ran revenue organizations and now choose portfolio work. Others are consultants who rebranded, or laid-off executives treating fractional work as a bridge to their next full-time role — which is not disqualifying but is worth knowing, because their attention will shift the moment a full-time offer appears.

Start with domain proximity, and be specific about what counts. Medical device revenue leadership is not interchangeable with pharma, with healthcare software, or with general B2B. The relevant experience is selling a physical product into hospitals, ambulatory surgery centers, or physician offices, through a process that includes clinical evaluation, value analysis, credentialing, and contract vehicles. Ask directly: name three health systems you have sold into, describe the value analysis process at each, and tell me how long it took from champion to purchase order. Someone who has done this will answer in specifics and with visible weariness. Someone who has not will answer in frameworks.

Distinguish capital equipment from disposables and implants, too. Capital sales are budget-cycle-driven, often involve a formal capital request process with an annual window, and can be displaced to the following fiscal year by a single missed deadline. Disposables and implants are consumption-driven, live or die on contract inclusion and reorder behavior, and reward a completely different coverage model. A candidate whose entire career is capital equipment will bring the wrong instincts to a consumables business, and vice versa. Neither is a red flag; a candidate who does not acknowledge the difference is.

Next, test for operating depth rather than strategic vocabulary. Useful questions: Walk me through the last CRM stage set you designed and why each stage existed. Tell me about a comp plan you wrote and what behavior it accidentally produced. Describe a distributor relationship you terminated and how you protected the accounts. What is your actual method for deciding whether a rep is underperforming or under-territoried. Strong operators answer these with texture, including the parts that went badly. Weak candidates redirect to methodology names.

Check the portfolio load honestly. A fractional executive holding two or three concurrent clients at two days each is running a full week and is at capacity. Someone claiming five or six simultaneous engagements is either doing very light advisory work or is overcommitted. Ask how many clients they currently serve, at what day commitment, and when the newest one started. Ask what happens if two clients have a crisis in the same week.

Reference checks should target CEOs and boards, not just peers, and the most useful question is not "were they good" but "what did they change, and is it still in place six months later." The failure mode of fractional leadership is work that evaporates on departure — a methodology nobody kept using, a CRM that reverted to free-text stages, a comp plan that got rewritten the next January. Durability is the real quality signal.

Structure the shortlist as a short, paid engagement rather than a long interview. A two-to-four-week paid diagnostic with a defined deliverable tells you more than six conversations. You see how they interrogate a pipeline, whether reps open up to them, whether the written output is sharp or generic, and whether the CEO enjoys working with them. It costs real money and it is worth it, because the alternative is discovering the mismatch four months into a retainer.

Finally, watch for the specific failure modes this role carries. The tourist arrives with a playbook from a different industry and applies it without translation. The rebuilder wants to replace the entire team and the entire tool stack in the first sixty days, which in a small device business destroys more relationship capital than it creates. The reporter produces beautiful dashboards and never changes a single deal outcome. And the empire-builder gradually converts a two-day engagement into a full-time role without anyone deciding to make that hire. Naming these out loud during the interview is a reasonable thing to do; a good candidate will recognize them and tell you which one they have to guard against.

A decision framework for whether to hire one

The choice is rarely fractional versus nothing. It is fractional versus a full-time CRO, versus promoting an internal VP of Sales, versus the CEO continuing to run revenue personally, versus a project-scoped consultant. Each is right in different circumstances, and the honest answer for a given device business is usually determined by three variables: revenue scale, whether the core problem is strategic or executional, and how long the company can wait.

Below roughly five million in revenue, a full-time CRO is generally premature. The company does not yet have a repeatable motion for an executive to scale, and the cash is better spent on reps, clinical evidence, or product. Fractional leadership or a strong sales manager plus an engaged CEO is usually the right shape. Between five and roughly forty million, fractional is at its most useful — the company has enough complexity to need real leadership and enough constraint that a full executive package is painful. Above that, or when the company is preparing for a financing event or a scaled national launch, the argument for a permanent executive gets strong, and the best use of a fractional CRO becomes bridging the gap and helping define and recruit the permanent role.

The second variable is the nature of the problem. If the motion is known and working and the issue is execution volume, a VP of Sales or additional reps solves it more cheaply. If the motion itself is unclear — wrong channel, wrong target segment, wrong pricing structure, no repeatable qualification — that is a strategy problem, and adding reps to it just increases the burn rate of a broken system. Fractional CROs earn their fee on the second problem, not the first.

The third variable is time. Recruiting a full-time device revenue executive typically takes months from search kickoff to a start date, then another quarter before they are productive. A fractional executive can start within weeks. If the company is two quarters from a raise or from a board decision about the sales model, the timeline alone may decide it.

Once the decision is made, the contract should encode how success will be judged, because vague engagements produce vague outcomes. Reasonable ninety-day deliverables for a device business: a written revenue diagnosis with a reclassified pipeline; a redesigned CRM stage set with artifact-based exit criteria in production; a documented qualification standard the team is actually using in deal reviews; a channel recommendation with the evidence behind it; a territory and quota model with coverage math; and a board-ready revenue reporting pack. Reasonable six-month outcomes: measurable improvement in stage-to-stage conversion at the gates that were broken, forecast accuracy inside a defined band, and a named plan for permanent leadership.

Notice that closed revenue is deliberately not on the ninety-day list. In a business with a twelve-to-eighteen-month cycle, judging a revenue executive on bookings in their first quarter measures the previous regime's work. The leading indicators — pipeline created, stage conversion, forecast accuracy, cycle time at specific gates — are the honest scorecard, and a fractional CRO who pushes back on a short-horizon revenue target is demonstrating judgment rather than dodging accountability.

Related questions

How is a fractional CRO different from a sales consultant?

A consultant delivers analysis and recommendations; a fractional CRO holds line accountability. They run the forecast call, make hiring and territory decisions, sit in on deals, and answer to the board for the number. Consultants advise the leader; a fractional CRO is the leader, part-time.

Can one person cover both sales and marketing in a device business?

At small scale, yes, and that combination is much of the value. Below roughly twenty million in revenue, splitting sales and marketing leadership creates handoff friction. Above that, marketing usually needs its own leader and the fractional CRO shifts toward alignment and channel strategy.

What happens to the work when the engagement ends?

Only what was written down survives. Documented stage definitions, a functioning CRM, a written qualification standard, and a trained internal leader persist. Coaching habits and forecast discipline decay within a quarter unless someone owns them. Build the handoff into the engagement from day one.

Does a fractional CRO need regulatory or clinical background?

Not formally, but they must respect the constraints. Promotional claims, off-label discussion, and interactions with clinicians are governed by rules that a revenue leader from unregulated industries can violate without realizing it. Candidates who route messaging through regulatory and legal review by reflex are the safe hires.

How long should the engagement run?

Three to six months is a normal initial term, often extended to twelve. Under three months there is not enough time to see a device sales cycle move. Beyond eighteen months without a transition plan, the engagement has usually become a full-time role priced as a retainer.

FAQ

Is a fractional CRO worth it for a device company under ten million in revenue?

Often yes, and this is where the economics are most favorable, provided the problem is genuinely strategic. A company at that size with a working motion and hungry reps may be better served spending on clinical evidence or another territory. A company that cannot explain why deals stall, is guessing at direct-versus-distributor, and has a pipeline nobody trusts is losing more to that confusion than a retainer costs. The test is whether the CEO can articulate a repeatable path from first clinical conversation to purchase order. If not, that is the gap the role fills.

How quickly should we expect results?

Diagnostic clarity within four to six weeks — a reclassified pipeline, a clear read on the team, and a channel recommendation. Operational changes such as a rebuilt stage set, a qualification standard, and a functioning forecast process land within eight to twelve weeks. Movement in closed revenue lags the engagement by roughly one sales cycle, which in device businesses means twelve months or more. Any candidate promising a revenue turnaround inside a quarter either does not understand hospital purchasing or is telling you what you want to hear.

Will our sales team accept a part-time leader?

It depends almost entirely on presence and credibility. Reps accept a leader who has carried a bag into a hospital, who shows up for a value analysis meeting, and who removes obstacles rather than adding reporting. They reject one who appears on a video call once a week to ask why the forecast slipped. The practical fix is structural: consistent scheduled days, a standing pipeline review that never moves, field travel in the first month, and at least one visible win — an approval unblocked, a pricing exception secured, a bad process removed — inside the first six weeks.

Should the fractional CRO also own customer success and reorder revenue?

In device businesses, usually yes. A large share of lifetime value comes after the first sale — reorders, consumables, service contracts, and expansion into sister facilities within the same health system. Splitting acquisition from adoption creates a seam where accounts go quiet after installation and nobody notices for two quarters. Putting both under one revenue owner, even a part-time one, keeps usage data and reorder patterns in the same conversation as new pipeline.

What are the biggest risks of hiring a fractional CRO?

Three stand out. First, mismatch of domain — a leader from software or from a different device category applying instincts that do not transfer. Second, insufficient time — a one-day-per-week engagement asked to deliver a full go-to-market rebuild, which produces frustration on both sides. Third, no durability plan — changes that evaporate the week the engagement ends. All three are addressable in the contract: verify domain specifically, size the day commitment to the scope honestly, and require written artifacts as deliverables rather than only meetings.

How does this role interact with an existing VP of Sales?

The relationship has to be defined explicitly before the engagement starts, or it will be defined badly by accident. The workable pattern is that the fractional CRO owns strategy, structure, methodology, and board reporting while the VP owns daily execution, coaching, and the team. That works when the VP is genuinely strong at execution and the gap is strategic. It fails when the fractional CRO is quietly being used to evaluate or replace the VP without anyone saying so — the VP senses it within weeks, cooperation ends, and both roles become ineffective.

Sources

• Gartner — Future of Sales
• McKinsey — Pharmaceuticals and Medical Products insights
• Deloitte — Life Sciences and Health Care industry insights
• U.S. FDA — Overview of Device Regulation
• AdvaMed — Medical device industry association
• AHRMM — Association for Health Care Resource & Materials Management
• Harvard Business Review — Sales and marketing
• Bain & Company — Healthcare and Life Sciences
• SaaStr — sales leadership archives

Related on PULSE

• What should an SMB company look for in a fractional CRO in 2027?
• Is there a fractional CRO available near me in Boise in 2027?
• Is there a fractional CRO available near me in Pasadena in 2027?
• Is there a fractional CRO available near me in Massachusetts in 2027?
• Who is the best fractional Chief Revenue Officer in Middletown in 2027?
• Is there a fractional Chief Revenue Officer available near me in Detroit in 2027?